ArticleEuropean urology2018

Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk.

Daniel E Spratt et al.PubMed ↗Publisher ↗

No numbers read from the abstract.